The Science

Potent, super-potent, relentless: the three words that explain a peptide tan

By Published November 15, 20265 min read

The gray market talks about Melanotan II as if “strong” were one word. It isn’t. Tanning pharmacology turns on three levers, and the sales pitch blurs them. Separating them is the only way the phrase “super-potent agonist” means anything — and the only way to see which property a real drug would have to add, and which this compound already has too much of.

The hormone being amplified is α-MSH: a local, minutes-long message the skin makes after ultraviolet damage. Everything below is what the Arizona chemists did to that message. None of it is a dose, a schedule, or a route.

Potency: how little it takes to fire the lock

Potency is not “how dark you get.” It is how little of a molecule it takes to switch a receptor on.

The receptor reads a four-residue stretch in the middle of α-MSH, His-Phe-Arg-Trp. That stretch is the message. The rest of the peptide is scaffolding that holds the message in a shape the receptor can recognise, and that scaffolding is fragile: the natural phenylalanine at position 7 sits in the L-form, the form the body’s own enzymes expect, and they cut there.

Swap that L-phenylalanine for its mirror image, D-phenylalanine, and two things happen at once. The message is held in the shape that fits the receptor, and the enzymes that chew L-peptides don’t recognise the cut site. That is potency as a chemist means it: a key that still fits, and that is harder to snap. The assay that could see this, years before anyone cloned the receptor, was a piece of frog skin going dark (how the molecule was built in the dark).

A useful lab word for the same idea is the EC₅₀: the concentration that, in a dish, produces half of the maximum response. A lower EC₅₀ means a more potent compound in that assay. It is a comparison between molecules. It is not a human dose, and it cannot be turned into one. Anyone selling a number from an EC₅₀ table as a protocol is changing the subject.

Super-potency: the jump over the hormone itself

Super-potency is potency measured against the natural signal, and found to be in another league.

In 1980 Sawyer, Hruby, Hadley and colleagues published [Nle⁴, D-Phe⁷]α-MSH — norleucine in place of the oxidation-prone methionine, D-phenylalanine in place of L-phenylalanine. In the adenylate-cyclase assay, the cell’s own “receptor fired” readout, that peptide ran about 26 times α-MSH. On frog skin it darkened pigment at a small fraction of the concentration the natural hormone needed. They called it superpotent and ultralong. Melanotan I is that peptide, later approved as afamelanotide for a rare disease. Melanotan II is the cyclic descendant: same message, tied into a ring so the shape cannot unfold.

Three levers, and the one a real drug still needs Three stacked bars labelled potency, super-potency, and duration, each filled, and a fourth bar labelled selectivity left empty. The point is that Melanotan II turns up the first three and does not supply the fourth. What “strong” actually separates into The peptide turns up the first three. A drug would still have to add the fourth. Potency how little fires the lock Super-potency versus α-MSH Duration minutes become hours Selectivity not supplied — MC1R and the other four receptors alike
Potency, super-potency, and duration are three different claims. Melanotan II was built to maximise them. Selectivity — hitting the pigment receptor and not the others — is the property it does not have.

Read the 26-times figure as what it is: one assay, one paper, amphibian and cell-free pharmacology from 1980. It explains why the chemists knew they had beaten the natural hormone before the receptor had a name (Mountjoy and colleagues cloned the melanocortin receptors only in 1992). It does not say how a person should use anything. A number from a frog skin is not a number from a person.

Relentless: the signal that will not clock off

The third lever is time, and it is the one the body was most careful about.

Natural α-MSH is cleared in minutes. That is the control system. Two further edits defeat it. Norleucine at position 4 replaces a methionine that oxidises and falls apart. The D-phenylalanine resists the proteases aimed at the message. Cyclisation — stitching the chain into the ring that Melanotan II is — keeps the shape from flopping open, which is another way a peptide gets destroyed. The result is not a louder whisper. It is a whisper that does not stop when the body intended it to.

For a tan, the variable that matters is exposure over time, not a single peak. Pigment is a downstream product: the receptor stays occupied, cAMP stays up, the melanocyte keeps making melanin, and the colour outlasts the peptide. That fan of clocks — minutes for the hormone, hours for the analog, weeks for the pigment — is the pharmacokinetic story in a drug with no address. This page only needs the distinction: duration is not potency. A brief, potent pulse and a long, modest one are different drugs. Melanotan II is the long one, on purpose.

The lever that was never pulled

None of those three chooses a receptor.

α-MSH’s message fits more than MC1R. A systemic, protease-resistant copy reaches the appetite receptors, the arousal receptors, and the receptors in the brain, because nothing in the molecule addresses it to skin. Super-potency makes that worse, not better: less is required to occupy whatever receptor it finds, and it finds them for longer. The harms are not a side effect of the potency. They are the potency, arriving where a local signal was never sent.

Selectivity is the missing fourth word. A photoprotective drug for healthy people would have to hit MC1R and leave the others alone, and it would have to prove that the pigment is protection and not only colour. That specification is what a safe tanning drug would actually have to be. The gray-market compound is the demonstration of the first three levers without the fourth. Calling it “strong” is how the pitch hides which lever was never built.

Common questions

Why is Melanotan II so much stronger than the body's own hormone?

It is not a new signal. It is α-MSH rebuilt on three levers: it fires the receptor at a lower concentration (potency), the 1980 ancestor peptide did so far more readily than natural α-MSH in a lab assay (super-potency), and amino-acid swaps plus a ring shape keep the message from being destroyed in minutes (duration). Those are bench comparisons, not a dose.

Does more potency make a safer tan?

No. Potency is how little it takes to switch a receptor on. It does not choose which receptor, which tissue, or whether the pigment that follows is protective. A real photoprotective drug would need selectivity — MC1R, and not the rest of the family — which the gray-market peptide does not have.

What is an EC50?

In a lab assay, the EC50 is the concentration that produces half of the maximum effect. A lower EC50 means a more potent compound in that dish. It is a comparison between molecules under controlled conditions, not a human dose and not a schedule.